Explain this page
Arphra AIPlain-English read on Amphastar Pharmaceuticals, Inc.’s valuation06-08today
- Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth10d
- Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses12d
- Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses12d
- Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag16d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$116.51
+519.43% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
12bull1bear
±5% threshold
Analyst PT consensus: $20.50 (+8.98%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.09% | -6.46% | +4.04% | -3.54% | -29.29% | -29.76% | -23.41% | -66.28% | -6.79% | +27.01% | +114.97% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$18.81
607 sh
Bid
$15.50
1 sh
Ask
$20.39
51 sh
Spread
$4.890
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $183.11M | $24.43M | $0.51 |
| Q3 Sep 2025 | $191.84M | $17.35M | $0.37 |
| Q2 Jun 2025 | $174.41M | $31.03M | $0.64 |
| Q1 Mar 2025 | $170.53M | $25.29M | $0.51 |
| Q4 Dec 2024 | $186.52M | $37.96M | $0.74 |
| Q3 Sep 2024 | $188.82M | $40.43M | $0.78 |
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growthmarketbeat.com·Jun 10, 2026
- Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Lossesglobenewswire.com·Jun 08, 2026
- Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Lossesglobenewswire.com·Jun 08, 2026
- Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Dragmarketbeat.com·Jun 04, 2026
- Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metricszacks.com·May 07, 2026
- Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimateszacks.com·May 07, 2026
- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026accessnewswire.com·May 07, 2026
- Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conferenceaccessnewswire.com·May 06, 2026
Recent analyst activity
DB- Jun 03, 2026PT$20.00Amphastar price target lowered to $20 from $23 at BarclaysBarclays
Peers
No peer list available for AMPH.
Total assets
$1.63B
Total debt
$656M
Cash & equiv
$170.18M
Operating CF
$156.12M
Free cash flow
$121.23M
Buybacks
-$75.59M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $719.89M | $140.4M | $98.09M | $2.03 | +13.63% |
| FY 2024 | $731.97M | $205.42M | $159.52M | $3.06 | +21.79% |
| FY 2023 | $644.4M | $196.99M | $137.55M | $2.60 | +21.34% |
| FY 2022 | $498.99M | $107.5M | $91.39M | $1.74 | +18.31% |
| FY 2021 | $437.77M | $69.89M | $62.12M | $1.25 | +14.19% |